VX19-809-124: A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Project: Research project

Project Details

Effective start/end date2/21/208/31/50


  • Vertex Pharmaceuticals Incorporated